Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Dr. Tim Sayed. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr. Tim Sayed or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Ep. 22 - Oral GLP-1 Breakthroughs and the Future of Weight Loss

30:23
 
Share
 

Manage episode 520110440 series 3635298
Content provided by Dr. Tim Sayed. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr. Tim Sayed or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

A new era of weight management is on the horizon. In this episode of The Scalpel’s Edge, learn how oral GLP-1 medications like semaglutide (Rebelsus) are changing the landscape of obesity care and cardiovascular health. Explore key findings from the OASIS-4 Phase 3 trial, new FDA updates, and what the data reveals about blood sugar control, heart health, and weight reduction across all age groups. Discover why oral options may soon rival injectables like Ozempic, Wegovy, and Mounjaro—and what this means for the millions of people seeking sustainable wellness solutions.

Contact Dr. Tim Sayed:
Phone: (858) 247-2933
Email: [email protected]
Website: timsayedmd.com
Instagram: @timsayedmd
YouTube: @Timsayedmd
Facebook: Tim Sayed MD

  continue reading

24 episodes

Artwork
iconShare
 
Manage episode 520110440 series 3635298
Content provided by Dr. Tim Sayed. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr. Tim Sayed or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

A new era of weight management is on the horizon. In this episode of The Scalpel’s Edge, learn how oral GLP-1 medications like semaglutide (Rebelsus) are changing the landscape of obesity care and cardiovascular health. Explore key findings from the OASIS-4 Phase 3 trial, new FDA updates, and what the data reveals about blood sugar control, heart health, and weight reduction across all age groups. Discover why oral options may soon rival injectables like Ozempic, Wegovy, and Mounjaro—and what this means for the millions of people seeking sustainable wellness solutions.

Contact Dr. Tim Sayed:
Phone: (858) 247-2933
Email: [email protected]
Website: timsayedmd.com
Instagram: @timsayedmd
YouTube: @Timsayedmd
Facebook: Tim Sayed MD

  continue reading

24 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play